Comparison of weekly and daily recall of pain as an endpoint in a randomized phase 3 trial of cabozantinib for metastatic castration-resistant prostate cancer

Abstract

Scant evidence reveals whether the use of weekly versus daily pain ratings leads to meaningful differences when measuring pain as a clinical trial outcome. We compared the ability of weekly ratings and descriptors of daily ratings to evaluate pain as an endpoint in a randomized phase 3 drug trial.

Document Details

Document Type
Pub Defense Publication
Publication Date
Apr 22, 2021
Source ID
10.1177/17407745211009547

Entities

People

  • Antonia V Bennett
  • Elisabeth M Schaffer
  • Ethan M Basch
  • Gisela M Schwab

Organizations

  • Exelixis
  • United States Department of Defense
  • University of Colorado
  • University of North Carolina
  • University of North Carolina at Chapel Hill

Tags

Fields of Study

  • Mathematics
  • Psychology

Readers

  • Instructional Design and Training Evaluation.
  • Mental Health of Military Veterans with Posttraumatic Stress Disorder (PTSD): Risk Factors, Prevalence, Symptoms, and Treatment.
  • Oncology